EFTA02402412.pdf

From: Sent: Friday, March 24, 2017 1:48 PM To: jeffrey E. Subject: Re: Strong LDL reduction Data with decreas=d cardiovascular events You saved our dear friend TRL Good w=ekend rs Mount Sinai Heart dictated and sent from an iPhone kindly excuse typos On Mar 24, 2017, at 7:25 AM, jeffrey E. «= href="mailto:[email protected]">[email protected]> wrote:=br> thanks for the=article on evolcumab, it is clear that it reduces the Idl=nbsp; MARKER. much less clear on its role in reduction of incid=nts? you were a mensch with terje =div dir="ltr"> please note <=iv>The information contained in this communication is confidential, may b= attorney-client privileged, may constitute inside information, and is i=tended only for the use of the addressee. It is the property of JEEUnauthorized use, disclosure or copying of this communication or any pa=t thereof is strictly prohibited and may be unlawful. If you have receiv=d this communication in error, please notify us immediately by return=e-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy this communication and all c=pies thereof, including all attachments. copyright -all rights reserved<=r> EFTA_R1_01439842 EFTA02402412